We have changed our visitation policy for the safety of our patients and staff. Click here for the updated visitation policy and click here for information about COVID-19.

[LCID Study Number: 20193133]

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b

This is a multi-center study of XMT-1536 in patients with tumors likely to express NaPi2b, focusing on patients with platinum-resistant ovarian cancer and non-small cell lung cancer. The primary objective is to determine the maximum tolerated dose or recommended Phase 2 dose of a once every 4-week administration of XMT-1536 and to assess the safety and tolerability of XMT-1536.

Primary Contact Email: [email protected]

Primary Contact Phone: 781-744-3421